Related Experiment Video
Updated: Jan 8, 2026
06:59
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
11.4K
Characteristic Glycemic Patterns during Capivasertib Treatment Identified by Continuous Glucose Monitoring.
Hironori Takahashi1, Satoko Hatayama1, Tomohito Izumi1
1Division of Diabetes and Metabolism, Sendai City Hospital, Japan.
Internal Medicine (Tokyo, Japan)
|December 17, 2025
Summary
The AKT inhibitor capivasertib can cause significant hyperglycemia in breast cancer patients. This glucose dysregulation, marked by daytime spikes, resolves when treatment stops and requires careful patient monitoring.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Recurrent breast cancer presents significant treatment challenges.
- AKT inhibitors are emerging therapies for advanced cancers.
- Metabolic side effects of targeted therapies require characterization.
Purpose of the Study:
- To report a case of hyperglycemia associated with capivasertib treatment.
- To characterize the glycemic profile in a patient receiving an AKT inhibitor.
- To investigate the potential mechanisms of capivasertib-induced hyperglycemia.
Main Methods:
- Continuous glucose monitoring (CGM) was employed to track glucose levels.
- The patient's glycemic response to intravenous glucose infusion was assessed.
- The impact of metformin on hyperglycemia was evaluated.
- Glucose profiles were compared during treatment and drug-free intervals.
Main Results:
- The patient developed pronounced daytime postprandial hyperglycemia and nocturnal-to-morning decline.
- Hyperglycemia resolved during drug-free intervals.
- Metformin was ineffective in controlling the hyperglycemia.
- Intravenous glucose infusion exacerbated the hyperglycemia.
Conclusions:
- Capivasertib-induced hyperglycemia may result from impaired glucose uptake and dysregulated hepatic glucose output due to AKT inhibition.
- Continuous glucose monitoring is crucial for identifying specific glycemic patterns.
- Individualized glycemic management strategies are essential for patients on AKT inhibitors.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562
01:26Glucose Absorption Into the Small Intestine
34.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.7K
01:16Insulin: Dosing Regimen and Adverse Effects
656
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
656
01:06Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
01:02Glucose Homeostasis: Regulation of Blood Glucose
3.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.7K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505